In this study, 1 of the criteria for defining intermediate- or high-risk smoldering multiple myeloma was clonal bone marrow plasma cells between 10% and less than 60%.
Researchers compared the monoclonal immunoglobulin rapid accurate measurement and matrix-assisted laser desorption/ionization-time of flight assays.
Neoantigens may have the ability to provoke the immune system into recognizing and killing cancer cells in patients with multiple myeloma.
Next-generation flow cytometry involves assessments of both plasma cell-surface antigens and immunoglobulin light-chain expression.
Despite an overall response rate of 57%, this clinical trial was suspended due to safety concerns then closed early due to insufficient activity of the study drug combination.